Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

5.160 -0.180 (-3.37%)

Streaming Delayed Price Updated: 9:44 AM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

31 32 Next >

Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart ↗

November 11, 2023

Our Psychedelic Drug Stocks Index continues to exhibit extreme volatility, declining 8% this week, jumping 22% the previous week and falling 6.5% the week before that. This week's decline is based on...

Via Talk Markets

Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗

November 06, 2023

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

Via Benzinga

Topics Economy

Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22% ↗

November 05, 2023

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances.

Via Talk Markets

Compass Pathways Plc (CMPS) Q3 2023 Earnings Call Transcript ↗

November 03, 2023

CMPS earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

COMPASS Pathways Q3 2023 Results: Cash Injection To Sustain Phase 3 Psilocybin Program ↗

November 02, 2023

COMPASS Pathways plc (NASDAQ: CMPS), the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30, showing:

Via Benzinga

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

November 02, 2023

From COMPASS Pathways

Via GlobeNewswire

Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗

October 29, 2023

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Via Benzinga

Topics Intellectual Property

COMPASS Pathways announces CFO transition

October 26, 2023

From COMPASS Pathways

Via GlobeNewswire

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗

October 22, 2023

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts

Via Benzinga

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗

October 16, 2023

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

Via Benzinga

Psychedelic-Compound-Based Drug Stocks Continue To Fall ↗

October 15, 2023

The 5 constituents in our Psychedelic Drug Stocks Index were down 10.1% this week (-6.3% last week) and are now down 39.2% since the end of July.

Via Talk Markets

The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It

October 12, 2023

--News Direct--

Via News Direct

The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It

October 12, 2023

By Faith Ashmore, Benzinga

Via TheNewswire.com

The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It ↗

October 11, 2023

Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among...

Via Benzinga

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

Major Psychedelic Drug Stocks Continued To Decline This Week ↗

October 06, 2023

A review of the performances of the 5 stocks in the Psychedelic Drug Stocks Index this week and since the end of August along with links to their latest news.

Via Talk Markets

COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care ↗

October 05, 2023

The Current Landscape Of Mental Health Is Failing Patients

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

September Summary: Largest Psychedelic Drug Stocks Dropped 14% ↗

October 01, 2023

Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining...

Via Talk Markets

Don’t Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher ↗

September 27, 2023

Psychedelic stocks should be part of a growth investor's portfolio due to the industry's ability to deliver strong return.

Via InvestorPlace

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price ↗

September 24, 2023

With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and...

Via Talk Markets

How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space

September 22, 2023

By Faith Ashmore, Benzinga

Via TheNewswire.com

Topics Artificial Intelligence

How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space

September 22, 2023

--News Direct--

Via News Direct

Topics Artificial Intelligence

One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

September 19, 2023

By Faith Ashmore, Benzinga

Via TheNewswire.com

One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

September 19, 2023

--News Direct--

Via News Direct

The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis

September 19, 2023

EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Economy

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗

September 18, 2023

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Via Benzinga

One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing ↗

September 18, 2023

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by...

Via Benzinga

4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗

September 17, 2023

4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.